Mereo BioPharma Group plc (NASDAQ:MREO) will be discussing 2Q20 financial results with the investment community.on 29th September 2020 at 8:00 AM eastern time.
Those interested in listening to the conference call live via the Internet can visit www.mereobiopharma.com
Earnings Expectation
Mereo BioPharma Group plc is expected to report second quarter earnings results, before market open, on Tuesday 29th September 2020.
Mereo BioPharma Group plc, a biopharmaceutical company, acquires, develops, and commercializes therapeutics for the treatment of rare and specialty diseases. Its product candidates include BPS-804, a novel antibody, which is in Phase IIb clinical trial for the treatment of osteogenesis imperfecta; MPH-966, an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency; BGS-649, an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism; and BCT-197, an oral p38 MAP kinase inhibitor that has completed Phase II clinical trial to treat acute exacerbations of chronic obstructive pulmonary disease. The company also develops OMP-305B83 and OMP-313M32, which are anti-cancer therapeutic candidates in clinical development stage.
